amodiaquine hydrochloride / Generic mfg. - LARVOL DELTA

Elucidation of a Novel Protective Function of AADAC Against Drug-induced Liver Injury through Ferroptosis Suppression (PubMed, Yakugaku Zasshi) - "Using Aadac knockout (KO) mice, we demonstrated that CCl4, APAP, and amodiaquine induced more severe liver damage in the absence of Aadac, with elevated ferrous (Fe2+) levels, lipid peroxidation, and oxidative stress...Furthermore, human AADAC overexpression in Huh-7 cells similarly reduced intracellular Fe2+ levels and conferred protection against CCl4-induced cytotoxicity in a ceruloplasmin-dependent manner. These findings reveal a novel, non-catalytic role for AADAC in iron homeostasis and ferroptosis suppression, suggesting its clinical significance in DILI susceptibility and therapy."

Journal • Review • Hepatology • Liver Failure • Oncology • AADAC

Chemoproteomics-based profiling elucidates the antimalarial effects of amodiaquine through disruption of glycolysis process in Plasmodium falciparum. (PubMed, Cell Commun Signal) - No abstract available

Journal • Infectious Disease

Amodiaquine Enhances Anti-Melanoma Efficacy of Attenuated Salmonella via Targeting Glutathione Reductase in Neutrophils. (PubMed, Adv Sci (Weinh)) - "A GR-shRNA-loaded VNP strain was further engineered and significantly potentiated VNP's antimelanoma effects. Our work not only advances the understanding of VNP-immune-tumor crosstalk but also provides a potential translational strategy that integrates drug repurposing with synthetic biology for developing microenvironment-smart therapeutics."

Journal • Melanoma • Oncology • Solid Tumor

Amodiaquine hydrochloride facilitates mycobacterial clearance via triggering autophagy in macrophages. (PubMed, Int J Antimicrob Agents) - "In vivo studies using the BALB/c mouse model demonstrated that CAS treatment significantly reduced bacterial load in lungs. Taken together, our findings highlight CAS as a novel host-directed therapeutic agent capable of enhancing the intracellular clearance of Mtb by triggering autophagy in macrophages."

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis • ULK1

Histamine N-methyltransferase upregulation, cardiac hypertrophy, and heart failure. (PubMed, Eur Heart J) - "HNMT exacerbates pathological hypertrophy and HF through SAM/FZD2/CaMKII axis. Amodiaquine, the inhibitor of HNMT, shows therapeutic potential against HF. Urinary N-methylhistamine emerges as a non-invasive HF biomarker."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • EZH2 • FZD2

Lessons from using SALAMA (DIGIT HCM-health campaign management platform) to implement and optimize seasonal malaria chemoprevention in Nampula, Mozambique. (PubMed, Oxf Open Digit Health) - "Key results included improved sulfadoxine-pyrimethamine plus amodiaquine administration, enhanced data use for daily decision-making and early identification of outliers. Importantly, the digital approach allowed for the visualization of the proportion of first-day doses recorded digitally in real time and the direct observation of therapy adherence, an important indicator of seasonal malaria chemoprevention campaign quality. This experience highlights how digital innovations, when well-coordinated and adapted to local contexts, can enhance malaria prevention and provide a case study to inform the scaling digital health interventions across public health programmes in Mozambique."

Journal • Infectious Disease • Malaria

ALAQ: Pharmacokinetic Study of Artemether-lumefantrine and Amodiaquine in Healthy Subjects (clinicaltrials.gov) - P1 | N=8 | Terminated | Sponsor: University of Oxford | N=16 ➔ 8 | Trial completion date: Aug 2026 ➔ Apr 2025 | Recruiting ➔ Terminated | Trial primary completion date: Aug 2026 ➔ Apr 2025; The decision was made due to the expired investigational drug and regulatory changes by the Thai FDA, along with increased importation costs. The research team and investigational drug sponsor agreed to seek approval for early project termination.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination

PMC-VAC: Perennial Malaria Chemoprevention in the Malaria Vaccine Era (clinicaltrials.gov) - P4 | N=1290 | Not yet recruiting | Sponsor: Stanford University

New P4 trial • Infectious Disease • Malaria

Mapping the prevalence of molecular markers of Plasmodium falciparum artemisinin partial resistance in Africa: a spatial-temporal modelling study. (PubMed, medRxiv) - "Partner drug amodiaquine marker mdr1 86Y is fading, but crt 76T remains prevalent in the Horn of Africa. This suggests the need to more broadly shift away from reliance on artemether-lumefantrine and necessitates greater molecular surveillance in sub-Saharan Africa, prioritizing the identified high-prevalence regions (Uganda, Rwanda, Ethiopia, Eritrea) and neighboring countries. Our integrated approach provides the foundational, evidence-based tools needed by national malaria control programs (NMCPs) and the WHO to refine drug policy decisions before ART-R develops into clinical treatment failure."

Biomarker • Journal • Infectious Disease • Malaria • ABCB1

Trends in Plasmodium falciparum resistance markers to sulfadoxine-pyrimethamine and amodiaquine over ten years of seasonal malaria chemoprevention in Moissala Health District, Chad. (PubMed, Malar J) - "Surveillance of molecular markers of resistance conducted over a ten-year period in Moissala Health District indicates that SP and AQ remain effective despite prolonged use. However, the rise in quadruple mutants-linked to partial SP resistance-is concerning, and monitoring is needed to detect any increase in quintuple mutants, which confer stronger resistance. These findings underscore the importance of sustained molecular surveillance to guide policy decisions and enable timely adaptations of SMC strategies as resistance patterns evolve."

Journal • Infectious Disease • Malaria • ABCB1 • DHFR

Inhibiting catalytic activity of Plasmodium falciparum aspartate protease Plasmepsin V: A biochemical approach to malaria intervention. (PubMed, Biochimie) - "In this study, the quinoline-based drugs amodiaquine (AQ) and clioquinol (CQ) are repurposed to inhibit the catalytic activity of PfPlmV...In contrast, CQ fails to bind at the catalytic site and does not exhibit any inhibitory effect on PfPlmV activity. These mechanistic insights will lay the foundations for new biochemical approaches to develop targeted therapies aimed at malaria disease."

Journal • Infectious Disease • Malaria

Amodiaquine Modulates Aggregation and Disassembly of Amyloid-β and Tau and Attenuates Neuroinflammatory Responses and Aβ Production. (PubMed, Pharmaceutics) - "In APP-H4 cells, 10 μM AQ decreased the level of Aβ compared to the control. AQ modulates both Aβ and tau aggregation and attenuates neuroinflammation and reduces Aβ pathology, supporting its potential as a dual-target therapeutic candidate for AD."

Journal • Alzheimer's Disease • CNS Disorders • Infectious Disease • Inflammation • IL6 • TNFA

Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi (clinicaltrials.gov) - P4 | N=1000 | Active, not recruiting | Sponsor: Liverpool School of Tropical Medicine | Recruiting ➔ Active, not recruiting

Enrollment closed • Anemia • Hematological Disorders • Infectious Disease • Malaria

FD-TACT: A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines (clinicaltrials.gov) - P3 | N=1680 | Recruiting | Sponsor: University of Oxford | Not yet recruiting ➔ Recruiting | Trial completion date: May 2025 ➔ Jul 2026 | Trial primary completion date: Nov 2024 ➔ Jul 2026

Enrollment open • Head-to-Head • Trial completion date • Trial primary completion date • Infectious Disease • Malaria

DeTACT-Africa: A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs. (clinicaltrials.gov) - P3 | N=2583 | Completed | Sponsor: University of Oxford | Recruiting ➔ Completed

Head-to-Head • Trial completion • Infectious Disease • Malaria

WITHDRAWN Understanding cohort retention: findings from a seasonal malaria chemoprevention efficacy study in Niassa, Mozambique (ASTMH 2025) - "This analysis utilised data from a CPES in which a cohort of children were prospectively recruited in four communities, underwent a baseline assessment, received a three-day course of sulfadoxine-pyrimethamine plus amodiaquine (SPAQ) and were followed up for up to 28 days to monitor incidence of malaria infection. There was substantial attrition in the study. Dropout rates varied across study communities, suggesting the influence of individual and contextual factors."

Clinical • Infectious Disease • Malaria

WITHDRAWN Assessing spatial and temporal trends in seasonal malaria chemoprevention coverage and other key indicators, and identifying factors associated with the trends in Nampula Province, Mozambique. (ASTMH 2025) - "In 2020, a mid-term review of Mozambique's Malaria Strategic Plan recommended the adoption of seasonal malaria chemoprevention (SMC) using sulfadoxine-pyrimethamine plus amodiaquine (SPAQ) to accelerate malaria control. Conversely, children whose caregivers had limited SMC knowledge had lower odds of receiving Day 1 SPAQ compared with those of more knowledgeable caregivers (Odds ratio, 0.68 [95% CI: 0.47- 0.98]). Future interventions should focus on strengthening caregiver engagement and refining distribution strategies, especially in underperforming districts."

Infectious Disease • Malaria

Pharmacometric evaluation of sulfadoxine-pyrimethamine- amodiaquine and dihydroartemisinin-piperaquine seasonal malaria chemoprevention in northern Uganda. (PubMed, Clin Infect Dis) - "SPAQ SMC had low clinical and parasitological chemopreventive efficacy in Northern Uganda whereas dihydroartemisinin-piperaquine was effective."

Journal • Infectious Disease • Malaria

Is Seasonal Malaria Chemoprevention with Sulfadoxine-Pyrimethamine/Amodiaquine Appropriate in East Africa? (PubMed, Clin Infect Dis) - No abstract available

Journal • Infectious Disease • Malaria

Parasitological efficacy of seasonal malaria chemoprevention in Nampula, northern Mozambique. (PubMed, Trans R Soc Trop Med Hyg) - "In Nampula, northern Mozambique, amodiaquine had low parasitological efficacy and sulphadoxine and pyrimethamine did not contribute significantly to chemoprevention."

Journal • Infectious Disease • Malaria

Quinine-Hemin Compound As an Anti-Inflammatory Therapy in Sickle Cell Disease (ASH 2024) - "In addition to quinine, we tested the effect of combination hemin with chloroquine, amodiaquine, and dihydroartemisinin on IL-1β, and no effect was identified at the concentration of 2.5 µM. Our data support that QHC inhibits inflammasome activation both in vitro and in vivo. In summary, our data support the use of hemin-binding small molecules as potential therapeutics for SCD and other inflammasome activated diseases."

Genetic Disorders • Hematological Disorders • Infectious Disease • Inflammation • Malaria • Sickle Cell Disease • HPX • IFNB1 • IL1B • IL6 • NLRP3 • TNFA

Global medium-term research priority setting for seasonal malaria chemoprevention: results from an eDelphi study. (PubMed, BMJ Glob Health) - "Research priorities related to sustainability, antimalarial resistance, integration with other interventions and improving quality of SMC delivery featured prominently among the highest-ranked research priorities. It is hoped the results of this consultation can encourage research uptake, guide new research and inform programme adaptation."

Journal • Infectious Disease • Malaria

Low pfcrt-76T and High pfdhfr-dhps Quadruple Mutant Genotype Prevalence after 10 Years of Seasonal Malaria Chemoprevention Implementation in Mali (AMP 2025) - "In 2014, SMC increased the prevalence of molecular markers of Plasmodium falciparum resistance to sulfadoxinepyrimethamine (SP) in the treated children but not in the non-SMC population...Children aged 3 to 59 months received several rounds of SP plus amodiaquine (SP+AQ) over 10 malaria seasons... SMC increased the prevalence of quadruple mutant of P. falciparum resistance to SP in the treated children and non-SMC population 10 years after SMC scale-up in Mali. In contrast, a low prevalence of pfcrt-76T was observed after several years of SMC implementation in Mali."

Infectious Disease • Malaria • ABCB1 • DHFR

Peripheral immune cell-specific genes in Parkinson's disease uncovered by multi-omics with therapeutic implications. (PubMed, NPJ Parkinsons Dis) - "Drug repurposing analysis identified several candidate compounds, including felodipine, amodiaquine, alprazolam, and tetrandrine, some of which are predicted to cross the blood-brain barrier. Molecular docking simulations further supported strong binding interactions between these compounds and PD-associated targets such as CTSB and ARSA. This integrative approach highlights key immune-cell-specific genes involved in PD and proposes several repurposable drugs with central nervous system potential, paving the way for more targeted therapeutic strategies."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease • CD4 • CD8 • FDFT1 • HLA-DQA1

Logistics Preparedness: Ensuring Timely Commodity Availability for Large-Scale ITN and SMC Integrated Malaria Campaigns (ASTMH 2025) - "Strategic logistics planning and execution were implemented to support the large-scale delivery of ITNs and Sulfadoxine Pyrimethamine and Amodiaquine (SPAQ) for SMC to each of the states ahead of the integrated campaigns. These strategies ensured commodity availability in integrated malaria campaigns that could be replicated in future integrated health interventions. Strengthening logistics preparedness for integrated malaria campaigns in Nigeria remains a cornerstone of achieving universal health coverage while ensuring commodity availability for malaria elimination."

Infectious Disease • Malaria